



CDDF WORKSHOP

29 - 30 November 2021

AMSTERDAM (NL)

*Gene- and Cell Therapies
in Oncology*



CDDF Multi-stakeholder Workshop

Gene- and Cell therapies in Oncology

29-30 November 2021

Amsterdam

Meeting Secretariat

Giorgia Campagnano (Event Coordinator, CDDF) : giorgia@cddf.org

PROGRAMME COMMITTEE

- Catarina Edfjäll (CDDF, SE)
- Simona Paratore (Novartis, IT)
- Darko Milijkovic (GSK, CH)
- Martina Schuessler-Lenz (Paul-Ehrlich-Institut, DE)
- Hans Scheuer (Myeloma Patients Europe, BE)
- Natacha Bolaños (Lymphoma Coalition, ES)

The target is a multidisciplinary audience of academia representatives, EU and US regulatory bodies (EMA, FDA, National Agencies), pharmaceutical Industry, HTAs and patient advocates

EXPECTED NUMBER OF PARTICIPANTS:

+/- 60 participants

MEETING DATE:

Monday 29 November to Tuesday 30 November, 2021

MEETING VENUE:

Van der Valk Hotel Amsterdam – Amstel

<https://www.vandervalkamsterdam.com/>

Address: Joan Muyskenweg 20, 1096 CJ Amsterdam, Netherlands

Phone: +31 (0)20 800 1100

DRAFT PROGRAMME

DAY 1 (Monday 29 November 2021)

Session 1: WHO is the Gene and Cell Cancer-killer: Deep dive on the Gene and cell scientific approaches in oncology

Session chairs: Simona Paratore (Novartis, IT) & Alessandro Aiuti (San Raffaele Telethon Institute for gene therapy, IT)

13:00-13:45	Lunch
13:45-14:05	Welcome note
14:05-14:20	Cancer killer profile: T cell fitness, autologous or allo T cell, Tcell or NK ?
14:20-14:35	How to generate a cancer killer: is the use of a virus the way? CART or TCR ? Emma Morris (University College London, UK)
14:35-14:50	Tumor and immunological environment influences in haematologic and solid tumors: engineering techniques or drug combination?
14:50-15:30	Panel Discussion
15:30-16:00	Coffee break

Session 2: How to develop a Gene and Cell cancer killer: the clinical trials. Challenges in timely initiation and conduct of clinical trials in Gene and Cell therapies in hematology. From planning to trial authorisation to patient treatment and follow up

Session chairs: Martina Schuessler-Lenz (Paul-Ehrlich-Institut, DE) & Ulrich Jaeger (Medical Universit Wien, AT)

16:00-16:10	Session opening
16:10-16:25	From clinical trials to marketing authorisation of advanced therapies Martina Schuessler-Lenz, PEI; EMA Committee for Advanced Therapies chair
16:25-16:40	Approval pathways for innovative gene & cell therapies Adnan Jaigirdar or Peter Bross (FDA, USA)
16:40-16:55	Clinical trials with gene and cell therapies – challenges and opportunities. The industry perspective
16:55-17:10	Challenges and learnings in conducting clinical trials with gene and cell therapies – the investigator perspective
17:10-17:50	Panel discussion
19:00-22:00	Networking dinner

DAY 2 (Tuesday 30 November 2021)

Session 3: HOW to bring a Gene and Cell cancer killer to patients: logistic matter.

Session chairs: Catarina Edfjaell (CDDF, SE) and Hans Scheurer (Myeloma Patients Europe, BE)

10:30-10:40	Session opening
10:40-10:55	From marketing authorisation to patient access - the rollout from the industry perspective
10:55-11:10	Patient perspective
11:10-11:25	HTA - reimbursement models
11:25-12:00	Panel Discussion
12:00-13:00	Lunch

Session 4: FUTURE PERSPECTIVE in the ECO-SYSTEM

Session chairs: Darko Milijkoic (GSK, CH) & Axel Glasmacher (CDDF, DE)

13:00-13:10	Session opening - polls
13:10-13:25	The European Society for Blood and Marrow Transplantation Nicolaus Kroeger (Medical Center Hamburg-Eppendorf, DE)
13:25-13:45	Synthetic Control Arm
13:45-14:00	Artificial Intelligence
14:00-14:40	Panel discussion
14:40-14:45	Farewell